Biosimilars Market Analysis Europe, North America, Asia, Rest of World (ROW) - US, Germany, UK, China, Republic of Korea - Size and Forecast 2023-2027

Published: Nov 2022

Pages: 172

SKU: IRTNTR70710

Snapshot

Biosimilars Market Analysis Report 2023-2027:

The Biosimilars Market size is estimated to grow by USD 42.23 billion between 2022 and 2027 accelerating at a CAGR of 23% during the forecast period.

This market report extensively covers market segmentation by product type (monoclonal antibodies, insulin, human growth hormone, and others), application (oncology and hematology, endocrinology, immunology, and nephrology), and geography (Europe, North America, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges.

What will be the Size of the Biosimilars Market During the Forecast Period?

To learn more about this report, Request Free Sample

Biosimilars Market Segmentation by Product Type, Application, Geography

Product Type Analysis

Based on application, the oncology, and hematology sub-segment is forecasted to have the largest market share. Since oncological and hematological disorders are prevalent, therefore, patients look for less expensive options. For the past two decades, biologics are playing major roles in cancer treatment and account for a significant share of the total market. Biosimilars are the ideal option when it comes to a reduction in costs. For the past two decades, biologics are playing major roles in cancer treatment and account for a significant share of the total market. The first biosimilar agents, erythropoiesis-stimulating agents, which are used as oncology support, were approved in the EU in 2007. MVASI was the first biosimilar to be approved by the US FDA for the treatment of cancer in September 2017.

Get a glance at the market contribution of various segments View a PDF Sample

The oncology and hematology segment was valued at USD 5.01 billion. The first biosimilar agents, erythropoiesis-stimulating agents, which are used as oncology support, were approved in the EU in 2007. MVASI was the first biosimilar to be approved by the US FDA for the treatment of cancer in September 2017.

Endocrinology, immunology holds the second largest share based on application analysis. The use of biosimilars in the treatment of immunological conditions is increasing rapidly. The global biosimilars market for the immunology therapy area was valued at USD 2.93 billion in 2020 and is expected to reach USD9.31 billion by 2025. The expected increase in the market size could be attributed to the possible entry of biosimilars following the expiry of patents for presently available biologics for the treatment of autoimmune and rheumatic disorders during the forecast period.AbbVie

Product Type Analysis

Based on product type, the market is segmented into monoclonal antibodies, insulin, human growth hormone, and others. The market share growth by the monoclonal antibodies segment (mAbs) will be significant during the forecast period. Biosimilar mAbs represent an opportunity to increase access to mAbs the patients due to their lower costs. These are key drugs indicated for the treatment of various cancers and autoimmune disorders such as rheumatoid arthritis. The rapid development of biosimilars for complex mAbs is expected to accelerate market growth during the forecast period. The primary factors for this growth include the patent expiry of blockbuster mAbs, coupled with the approval of biosimilar mAbs, and the increasing prevalence of chronic diseases.

Biosimilar monoclonal antibodies (mAbs) are large, complex proteins used by the immune system to identify and neutralize foreign bodies such as bacteria and viruses. They are used for the treatment of cancers such as breast cancer and non-cancer diseases such as rheumatoid arthritis. They are also highly similar to the originator mAbs and cost-effective. Several vendors are developing biosimilar mAbs as they are cost-effective treatments. For instance, the European Union and the US FDA recently approved five trastuzumab biosimilars. Such an increasing number of biosimilar mAbs gaining approval will drive the market growth during the forecast period.

Regional Analysis

For more insights about the market share of various regions View PDF Sample now!

Europe is estimated to contribute 46% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers will shape the market during the forecast period.

The growth momentum in Europe is accelerating and is expected to increase to x% by 2025. Europe approved sixteen biosimilars of seven different biologic products in 2020, thus expanding the biosimilar market into new therapeutic areas and newer classes of biologics for which no biosimilars have been previously approved in the EU.

In many EU countries, including Germany and Sweden, biosimilar substitution is allowed for specific groups of biosimilars manufactured by the same pharmaceutical company. France is among the first EU country to establish a law for biosimilar substitution in treatment-naive patients or to continue a treatment already initiated with the same biosimilar. However, the implementation decree of the law is still pending, and in practice, biosimilar substitution is not yet implemented. In countries like Poland, the automatic substitution of biosimilars may be possible since there is no law or guidance at place.

Covid Recovery Analysis

The COVID-19 pandemic had a negative impact on the demand for biosimilars due to reduced focus on cancer and delays in cancer treatment procedures. However, key vendors are engaging in collaborations and mergers to adapt to the pandemic situation. Additionally, government initiatives, like the NIH's ACTIV partnership, are expected to support market growth by prioritizing and accelerating the development of effective treatments and vaccines for COVID-19.

Buy Now Full Report and Discover More

Key Biosimilars Market Players

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

Novartis- The company offers biosimilars for genetical industry.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Biosimilars Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges.

Key Biosimilars Market Drivers

The price advantage of biosimilars over biologics is a major biosimilars driver. The high cost of biologics limits patient access and increases healthcare expenses. Biosimilars, which are authorized copies of biologics, are priced 20%-25% lower than the original products. This cost reduction is due to fewer clinical trials required for biosimilars compared to the original biologics. Clinical trials typically use the original biologic as a comparator to establish equivalence. Additionally, biosimilars have no marketing or post-marketing research and development costs.

Advancements in genetic engineering and lower scale-up costs for producing recombinant proteins have made manufacturing biosimilars more cost-effective. Further cost reduction is possible by streamlining the approval process, and reducing unnecessary repetition of clinical trials through guideline modifications by organizations like EMA and the US FDA. The Biologics Price Competition and Innovation Act aim to promote biosimilars while still providing incentives for the development of original biologics.

Significant Biosimilars Market Trends

Patients' and physicians' willingness to switch to biosimilars is a major biosimilars market trend. The global biosimilar market is influenced by patient attitudes toward switching and physician prescribing practices. Many physicians, especially rheumatologists, prefer prescribing bio-originators as first-line or second-line therapy for rheumatology-related diseases. The main barrier to physician acceptance is the perception that biosimilars are less effective than reference products. Limited substitution of biosimilars with bio-originators is permitted in certain countries, primarily in Central and Eastern Europe, at the community pharmacy level. However, legislation in some regions hinders the widespread adoption of biosimilars.

Another challenge arises from the existence of multiple biosimilars approved for a single reference product, with no guidelines available for comparing these biosimilars with each other.

Major Biosimilars Market Challenges

Market access barriers for biosimilars are a major biosimilars market challenge hindering the growth of the market. Biosimilars face several challenges in their market entry and competition with biologics. One major challenge is the complex manufacturing process, which requires strict maintenance of product uniformity and can lead to variations between batches. This manufacturing complexity poses a significant hurdle for new companies entering the market, while established biologics manufacturers continue to dominate.

Legal issues related to the approval process for biologics are another challenge. The clinical trial process for a single biosimilar can be time-consuming, hindering timely approvals. Unlike generic drugs, substitution and interchangeability of biosimilars are not as feasible. Safety concerns, pricing considerations, and the acceptance of biosimilars by physicians and patients also present potential barriers to market entry.

Buy Now Full Report and Discover More

Key Biosimilars Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Biosimilars Market Customer Landscape

Segment Overview

The biosimilars market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.

Product Type Outlook ( USD Billion, 2017 - 2027)
- Monoclonal antibodies
- Insulin
- Human growth hormone
- Others
Application Outlook ( USD Billion, 2017 - 2027)
- Oncology and hematology
- Endocrinology
- Immunology
- Nephrology
Region Outlook ( USD Billion, 2017 - 2027)
- Europe
  - U.K.
  - Germany
  - France
  - Rest of Europe
- North America
  - The U.S.
  - Canada
- Asia
  - China
  - India
  - Singapore
- Rest of World (ROW)
  - Brazil
  - Argentina
  - Rest of the Middle East & Africa

Biosimilars Market Scope
Report Coverage	Details
Page number	172
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 23%
Market growth 2023-2027	USD 42.23 billion
Market structure	Fragmented
YoY growth 2022-2023(%)	22.9
Regional analysis	Europe, North America, Asia, and Rest of World (ROW)
Performing market contribution	Europe at 46%
Key countries	US, Germany, UK, China, and Republic of Korea
Competitive landscape	Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
Key companies profiled	AbbVie Inc., Amgen Inc., Biocon Ltd., Biogen Inc., Boehringer Ingelheim International GmbH, Celltrion Healthcare Co. Ltd., Dr Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, Gedeon Richter Plc, Halozyme Therapeutics Inc, Intas Pharmaceuticals Ltd., Mabion S.A., Novartis AG, Pfizer Inc., Samsung Biologics Co. Ltd., Sanofi SA, Teva Pharmaceutical Industries Ltd., and Viatris Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View Sample PDF at your Fingertips

What are the Key Data Covered in this Biosimilars Market Research Report?

CAGR of the market during the forecast period
Detailed information on factors that will drive the growth of the Biosimilars Market between 2023 and 2027
Precise estimation of the size of the biosimilars market size and its contribution of the market in focus to the parent market
Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria
Companies landscape comparing criticality of inputs and factors of differentiation
Exclusive Matrix on companies position and classification
Accurate predictions about upcoming trends and changes in consumer behavior
Growth of the market industry across Europe, North America, Asia, and Rest of World (ROW)
Thorough analysis of the market’s competitive landscape and detailed information about companies
Comprehensive analysis of factors that will challenge the growth of biosimilars market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

Table of Contents

1 Executive Summary

1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Product Type
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Application
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition

3.2 Market segment analysis
- Exhibit 13: Market segments

3.3 Market size 2022

3.4 Market outlook: Forecast for 2022-2027
- Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ billion)
- Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ billion)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

4.1 Global biosimilars market 2017 - 2021
- Exhibit 18: Historic Market Size – Data Table on Global biosimilars market 2017 - 2021 ($ billion)

4.2 Product Segment Analysis 2017 - 2021
- Exhibit 19: Historic Market Size – Product Segment 2017 - 2021 ($ billion)

4.3 Application Segment Analysis 2017 - 2021
- Exhibit 20: Historic Market Size – Application Segment 2017 - 2021 ($ billion)

4.4 Geography Segment Analysis 2017 - 2021
- Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ billion)

4.5 Country Segment Analysis 2017 - 2021
- Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ billion)

5 Five Forces Analysis

5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Product Type

6.1 Market segments
- Exhibit 30: Chart on Product Type - Market share 2022-2027 (%)
- Exhibit 31: Data Table on Product Type - Market share 2022-2027 (%)

6.2 Comparison by Product Type
- Exhibit 32: Chart on Comparison by Product Type
- Exhibit 33: Data Table on Comparison by Product Type

6.3 Monoclonal antibodies - Market size and forecast 2022-2027
- Exhibit 34: Chart on Monoclonal antibodies - Market size and forecast 2022-2027 ($ billion)
- Exhibit 35: Data Table on Monoclonal antibodies - Market size and forecast 2022-2027 ($ billion)
- Exhibit 36: Chart on Monoclonal antibodies - Year-over-year growth 2022-2027 (%)
- Exhibit 37: Data Table on Monoclonal antibodies - Year-over-year growth 2022-2027 (%)

6.4 Insulin - Market size and forecast 2022-2027
- Exhibit 38: Chart on Insulin - Market size and forecast 2022-2027 ($ billion)
- Exhibit 39: Data Table on Insulin - Market size and forecast 2022-2027 ($ billion)
- Exhibit 40: Chart on Insulin - Year-over-year growth 2022-2027 (%)
- Exhibit 41: Data Table on Insulin - Year-over-year growth 2022-2027 (%)

6.5 Human growth hormone - Market size and forecast 2022-2027
- Exhibit 42: Chart on Human growth hormone - Market size and forecast 2022-2027 ($ billion)
- Exhibit 43: Data Table on Human growth hormone - Market size and forecast 2022-2027 ($ billion)
- Exhibit 44: Chart on Human growth hormone - Year-over-year growth 2022-2027 (%)
- Exhibit 45: Data Table on Human growth hormone - Year-over-year growth 2022-2027 (%)

6.6 Others - Market size and forecast 2022-2027
- Exhibit 46: Chart on Others - Market size and forecast 2022-2027 ($ billion)
- Exhibit 47: Data Table on Others - Market size and forecast 2022-2027 ($ billion)
- Exhibit 48: Chart on Others - Year-over-year growth 2022-2027 (%)
- Exhibit 49: Data Table on Others - Year-over-year growth 2022-2027 (%)

6.7 Market opportunity by Product Type
- Exhibit 50: Market opportunity by Product Type ($ billion)

7 Market Segmentation by Application

7.1 Market segments
- Exhibit 51: Chart on Application - Market share 2022-2027 (%)
- Exhibit 52: Data Table on Application - Market share 2022-2027 (%)

7.2 Comparison by Application
- Exhibit 53: Chart on Comparison by Application
- Exhibit 54: Data Table on Comparison by Application

7.3 Oncology and hematology - Market size and forecast 2022-2027
- Exhibit 55: Chart on Oncology and hematology - Market size and forecast 2022-2027 ($ billion)
- Exhibit 56: Data Table on Oncology and hematology - Market size and forecast 2022-2027 ($ billion)
- Exhibit 57: Chart on Oncology and hematology - Year-over-year growth 2022-2027 (%)
- Exhibit 58: Data Table on Oncology and hematology - Year-over-year growth 2022-2027 (%)

7.4 Endocrinology - Market size and forecast 2022-2027
- Exhibit 59: Chart on Endocrinology - Market size and forecast 2022-2027 ($ billion)
- Exhibit 60: Data Table on Endocrinology - Market size and forecast 2022-2027 ($ billion)
- Exhibit 61: Chart on Endocrinology - Year-over-year growth 2022-2027 (%)
- Exhibit 62: Data Table on Endocrinology - Year-over-year growth 2022-2027 (%)

7.5 Immunology - Market size and forecast 2022-2027
- Exhibit 63: Chart on Immunology - Market size and forecast 2022-2027 ($ billion)
- Exhibit 64: Data Table on Immunology - Market size and forecast 2022-2027 ($ billion)
- Exhibit 65: Chart on Immunology - Year-over-year growth 2022-2027 (%)
- Exhibit 66: Data Table on Immunology - Year-over-year growth 2022-2027 (%)

7.6 Nephrology - Market size and forecast 2022-2027
- Exhibit 67: Chart on Nephrology - Market size and forecast 2022-2027 ($ billion)
- Exhibit 68: Data Table on Nephrology - Market size and forecast 2022-2027 ($ billion)
- Exhibit 69: Chart on Nephrology - Year-over-year growth 2022-2027 (%)
- Exhibit 70: Data Table on Nephrology - Year-over-year growth 2022-2027 (%)

7.7 Market opportunity by Application
- Exhibit 71: Market opportunity by Application ($ billion)

8 Customer Landscape

8.1 Customer landscape overview
- Exhibit 72: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
- Exhibit 73: Chart on Market share by geography 2022-2027 (%)
- Exhibit 74: Data Table on Market share by geography 2022-2027 (%)

9.2 Geographic comparison
- Exhibit 75: Chart on Geographic comparison
- Exhibit 76: Data Table on Geographic comparison

9.3 Europe - Market size and forecast 2022-2027
- Exhibit 77: Chart on Europe - Market size and forecast 2022-2027 ($ billion)
- Exhibit 78: Data Table on Europe - Market size and forecast 2022-2027 ($ billion)
- Exhibit 79: Chart on Europe - Year-over-year growth 2022-2027 (%)
- Exhibit 80: Data Table on Europe - Year-over-year growth 2022-2027 (%)

9.4 North America - Market size and forecast 2022-2027
- Exhibit 81: Chart on North America - Market size and forecast 2022-2027 ($ billion)
- Exhibit 82: Data Table on North America - Market size and forecast 2022-2027 ($ billion)
- Exhibit 83: Chart on North America - Year-over-year growth 2022-2027 (%)
- Exhibit 84: Data Table on North America - Year-over-year growth 2022-2027 (%)

9.5 Asia - Market size and forecast 2022-2027
- Exhibit 85: Chart on Asia - Market size and forecast 2022-2027 ($ billion)
- Exhibit 86: Data Table on Asia - Market size and forecast 2022-2027 ($ billion)
- Exhibit 87: Chart on Asia - Year-over-year growth 2022-2027 (%)
- Exhibit 88: Data Table on Asia - Year-over-year growth 2022-2027 (%)

9.6 Rest of World (ROW) - Market size and forecast 2022-2027
- Exhibit 89: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
- Exhibit 90: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ billion)
- Exhibit 91: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- Exhibit 92: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

9.7 Germany - Market size and forecast 2022-2027
- Exhibit 93: Chart on Germany - Market size and forecast 2022-2027 ($ billion)
- Exhibit 94: Data Table on Germany - Market size and forecast 2022-2027 ($ billion)
- Exhibit 95: Chart on Germany - Year-over-year growth 2022-2027 (%)
- Exhibit 96: Data Table on Germany - Year-over-year growth 2022-2027 (%)

9.8 US - Market size and forecast 2022-2027
- Exhibit 97: Chart on US - Market size and forecast 2022-2027 ($ billion)
- Exhibit 98: Data Table on US - Market size and forecast 2022-2027 ($ billion)
- Exhibit 99: Chart on US - Year-over-year growth 2022-2027 (%)
- Exhibit 100: Data Table on US - Year-over-year growth 2022-2027 (%)

9.9 UK - Market size and forecast 2022-2027
- Exhibit 101: Chart on UK - Market size and forecast 2022-2027 ($ billion)
- Exhibit 102: Data Table on UK - Market size and forecast 2022-2027 ($ billion)
- Exhibit 103: Chart on UK - Year-over-year growth 2022-2027 (%)
- Exhibit 104: Data Table on UK - Year-over-year growth 2022-2027 (%)

9.10 China - Market size and forecast 2022-2027
- Exhibit 105: Chart on China - Market size and forecast 2022-2027 ($ billion)
- Exhibit 106: Data Table on China - Market size and forecast 2022-2027 ($ billion)
- Exhibit 107: Chart on China - Year-over-year growth 2022-2027 (%)
- Exhibit 108: Data Table on China - Year-over-year growth 2022-2027 (%)

9.11 Republic of Korea - Market size and forecast 2022-2027
- Exhibit 109: Chart on Republic of Korea - Market size and forecast 2022-2027 ($ billion)
- Exhibit 110: Data Table on Republic of Korea - Market size and forecast 2022-2027 ($ billion)
- Exhibit 111: Chart on Republic of Korea - Year-over-year growth 2022-2027 (%)
- Exhibit 112: Data Table on Republic of Korea - Year-over-year growth 2022-2027 (%)

9.12 Market opportunity by geography
- Exhibit 113: Market opportunity by geography ($ billion)

10 Drivers, Challenges, and Trends

10.1 Market drivers

10.2 Market challenges

10.3 Impact of drivers and challenges
- Exhibit 114: Impact of drivers and challenges in 2022 and 2027

10.4 Market trends

11 Vendor Landscape

11.1 Overview

11.2 Vendor landscape
- Exhibit 115: Overview on Criticality of inputs and Factors of differentiation

11.3 Landscape disruption
- Exhibit 116: Overview on factors of disruption

11.4 Industry risks
- Exhibit 117: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
- Exhibit 118: Vendors covered

12.2 Market positioning of vendors
- Exhibit 119: Matrix on vendor position and classification

12.3 AbbVie Inc.
- Exhibit 120: AbbVie Inc. - Overview
- Exhibit 121: AbbVie Inc. - Product / Service
- Exhibit 122: AbbVie Inc. - Key offerings

12.4 Amgen Inc.
- Exhibit 123: Amgen Inc. - Overview
- Exhibit 124: Amgen Inc. - Product / Service
- Exhibit 125: Amgen Inc. - Key offerings

12.5 Biocon Ltd.
- Exhibit 126: Biocon Ltd. - Overview
- Exhibit 127: Biocon Ltd. - Business segments
- Exhibit 128: Biocon Ltd. - Key offerings
- Exhibit 129: Biocon Ltd. - Segment focus

12.6 Biogen Inc.
- Exhibit 130: Biogen Inc. - Overview
- Exhibit 131: Biogen Inc. - Product / Service
- Exhibit 132: Biogen Inc. - Key offerings

12.7 Boehringer Ingelheim International GmbH
- Exhibit 133: Boehringer Ingelheim International GmbH - Overview
- Exhibit 134: Boehringer Ingelheim International GmbH - Business segments
- Exhibit 135: Boehringer Ingelheim International GmbH - Key news
- Exhibit 136: Boehringer Ingelheim International GmbH - Key offerings
- Exhibit 137: Boehringer Ingelheim International GmbH - Segment focus

12.8 Celltrion Healthcare Co. Ltd.
- Exhibit 138: Celltrion Healthcare Co. Ltd. - Overview
- Exhibit 139: Celltrion Healthcare Co. Ltd. - Product / Service
- Exhibit 140: Celltrion Healthcare Co. Ltd. - Key offerings

12.9 Dr Reddys Laboratories Ltd.
- Exhibit 141: Dr Reddys Laboratories Ltd. - Overview
- Exhibit 142: Dr Reddys Laboratories Ltd. - Business segments
- Exhibit 143: Dr Reddys Laboratories Ltd. - Key offerings
- Exhibit 144: Dr Reddys Laboratories Ltd. - Segment focus

12.10 F. Hoffmann La Roche Ltd.
- Exhibit 145: F. Hoffmann La Roche Ltd. - Overview
- Exhibit 146: F. Hoffmann La Roche Ltd. - Business segments
- Exhibit 147: F. Hoffmann La Roche Ltd. - Key news
- Exhibit 148: F. Hoffmann La Roche Ltd. - Key offerings
- Exhibit 149: F. Hoffmann La Roche Ltd. - Segment focus

12.11 Fresenius SE and Co. KGaA
- Exhibit 150: Fresenius SE and Co. KGaA - Overview
- Exhibit 151: Fresenius SE and Co. KGaA - Business segments
- Exhibit 152: Fresenius SE and Co. KGaA - Key news
- Exhibit 153: Fresenius SE and Co. KGaA - Key offerings
- Exhibit 154: Fresenius SE and Co. KGaA - Segment focus

12.12 Gedeon Richter Plc
- Exhibit 155: Gedeon Richter Plc - Overview
- Exhibit 156: Gedeon Richter Plc - Business segments
- Exhibit 157: Gedeon Richter Plc - Key news
- Exhibit 158: Gedeon Richter Plc - Key offerings
- Exhibit 159: Gedeon Richter Plc - Segment focus

12.13 Halozyme Therapeutics Inc
- Exhibit 160: Halozyme Therapeutics Inc - Overview
- Exhibit 161: Halozyme Therapeutics Inc - Product / Service
- Exhibit 162: Halozyme Therapeutics Inc - Key offerings

12.14 Intas Pharmaceuticals Ltd.
- Exhibit 163: Intas Pharmaceuticals Ltd. - Overview
- Exhibit 164: Intas Pharmaceuticals Ltd. - Product / Service
- Exhibit 165: Intas Pharmaceuticals Ltd. - Key offerings

12.15 Mabion S.A.
- Exhibit 166: Mabion S.A. - Overview
- Exhibit 167: Mabion S.A. - Product / Service
- Exhibit 168: Mabion S.A. - Key offerings

12.16 Novartis AG
- Exhibit 169: Novartis AG - Overview
- Exhibit 170: Novartis AG - Business segments
- Exhibit 171: Novartis AG - Key offerings
- Exhibit 172: Novartis AG - Segment focus

12.17 Viatris Inc.
- Exhibit 173: Viatris Inc. - Overview
- Exhibit 174: Viatris Inc. - Business segments
- Exhibit 175: Viatris Inc. - Key offerings
- Exhibit 176: Viatris Inc. - Segment focus

13 Appendix

13.1 Scope of the report

13.2 Inclusions and exclusions checklist
- Exhibit 177: Inclusions checklist
- Exhibit 178: Exclusions checklist

13.3 Currency conversion rates for US$
- Exhibit 179: Currency conversion rates for US$

13.4 Research methodology
- Exhibit 180: Research methodology
- Exhibit 181: Validation techniques employed for market sizing
- Exhibit 182: Information sources

13.5 List of abbreviations
- Exhibit 183: List of abbreviations

Methodology

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

INFORMATION SOURCES

Primary sources

Manufacturers and suppliers
Channel partners
Industry experts
Strategic decision makers

Secondary sources

Industry journals and periodicals
Government data
Financial reports of key industry players
Historical data
Press releases

DATA ANALYSIS

Data Synthesis

Collation of data
Estimation of key figures
Analysis of derived insights

Data Validation

Triangulation with data models
Reference against proprietary databases
Corroboration with industry experts

REPORT WRITING

Qualitative

Market drivers
Market challenges
Market trends
Five forces analysis

Quantitative

Market size and forecast
Market segmentation
Geographical insights
Competitive landscape

Purchase Report

PURCHASE FULL REPORT OF

biosimilars market market

Buy Report - Single User License 2500 USD

QUICK BUY

Key Questions Answered

What are the key global market and the regional market share?
What are the revenue-generating key market segments?
What are the key factors driving and challenging this market’s growth?
Who are the key market vendors and their growth strategies?
What are the latest trends influencing the growth of this market?
What are the variables influencing the market growth in the primary regions?
What are the factors influencing the growth of the parent market?

Why should you prefer Technavio's market insights report?

Off-the-shelf research reports
Reports can be tailored to meet the customer's needs
Trusted by more than 100 fortune 500 organizations
Information about the market's key drivers, trends, and challenges
Parent market analysis
Every week, 50,000 people visit our subscription platform
Detailed vendors report with competitive landscape
Covid-19 impact and recovery analysis
Data on revenue-generating market segments
Details on the market shares of various regions
Five-force market analysis